Positions

Selected Publications

Academic Article

Year Title Altmetric
2019 Differential escape mechanisms in cetuximab-resistant head and neck cancer cells.  Biochemical and Biophysical Research Communications.  517:36-42. 2019
2019 Stereotactic radiosurgery with MLC-defined arcs: Verification of dosimetry, spatial accuracy, and end-to-end tests.  Journal of Applied Clinical Medical Physics.  20:84-98. 2019
2019 Pathologic Predictors of Local Recurrence in Atypical Meningiomas Following Gross Total Resection 2019
2018 The virtual cone: A novel technique to generate spherical dose distributions using a multileaf collimator and standardized control-point sequence for small target radiation surgery.  Advances in Radiation Oncology.  3:421-430. 2018
2018 MicroRNA-31 is required for astrocyte specification.  Glia.  66:987-998. 2018
2017 Macropinocytosis of bevacizumab by glioblastoma cells in the perivascular niche affects their survival.  Clinical Cancer Research.  23:7059-7071. 2017
2017 Fractionated stereotactic radiation therapy for intact brain metastases.  Advances in Radiation Oncology.  2:564-571. 2017
2017 Molecular-based recursive partitioning analysis model for glioblastoma in the temozolomide era a correlative analysis based on nrg oncology RTOG 0525.  JAMA Oncology.  3:784-792. 2017
2016 Coneless Linear Accelerator-Based Volumetric Modulated Arc Therapy Stereotactic Radiosurgery Technique for Functional Disorders. 2016
2016 Distant Brain Recurrence in Patients With 5 or More Newly Diagnosed Brain Metastases Treated With Stereotactic Radiosurgery (SRS) or Fractionated Stereotactic Radiation Therapy (FSRT) Alone. 2016
2016 Stereotactic Hypofractionated Radiation Therapy for Intact Brain Metastases. 2016
2015 Enhancement of Cetuximab-Induced Radiosensitization by JAK-1 Inhibition.  BMC Cancer.  15. 2015
2015 Neuronal activity promotes glioma growth through neuroligin-3 secretion.  Cell.  161:803-816. 2015
2014 A20 expressing tumors and anticancer drug resistance.  Advances in Experimental Medicine and Biology.  809:65-81. 2014
2013 Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma.  Clinical Cancer Research.  19:6484-6494. 2013
2013 Feature selection and survival modeling in The Cancer Genome Atlas.  International Journal of Nanomedicine.  8:57-62. 2013
2013 RTOG 0211: A phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients 2013
2012 Laminin alpha 2 enables glioblastoma stem cell growth.  Annals of Neurology.  72:766-778. 2012
2012 Molecular profiling indicates orthotopic xenograft of glioma cell lines simulate a subclass of human glioblastoma.  Journal of Cellular and Molecular Medicine.  16:545-554. 2012
2011 Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2.  Cell.  146:53-66. 2011
2011 Nonreceptor Tyrosine Kinase BMX Maintains Self-Renewal and Tumorigenic Potential of Glioblastoma Stem Cells by Activating STAT3.  Cancer Cell.  19:498-511. 2011
2010 A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas.  Cancer.  116:5297-5305. 2010
2009 Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults.  BMC Cancer.  9:372. 2009
2009 A network model of a cooperative genetic landscape in brain tumors 2009
2009 Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas 2009
2008 Use of gene signatures to improve risk estimation in cancer 2008
2007 CHD5 Is a Tumor Suppressor at Human 1p36.  Cell.  128:459-475. 2007
2005 Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas.  Cancer Research.  65:8679-8689. 2005
2005 High-resolution genome-wide mapping of genetic alterations in human glial brain tumors.  Cancer Research.  65:4088-4096. 2005
2005 DNA topoisomerase IIalpha and Her-2/neu gene dosages in pediatric malignant gliomas..  International Journal of Oncology.  26:1187-1192. 2005
2003 Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: Evidence for distinct angiogenic subtypes.  Brain Pathology.  13:133-143. 2003
2002 Expression of DNA topoisomerase IIα in oligodendroglioma 2002
2002 High expression of DNA topoisomerase IIα and Ki-67 antigen is associated with prolonged survival in glioblastoma patients.  European journal of cancer.  38:1343-1347. 2002
2002 DNA topoisomerase IIα predicts progression-free and overall survival in pediatric malignant non-brainstem gliomas.  International Journal of Cancer.  99:817-820. 2002
2002 Expression of DNA topoisomerase IIalpha in oligodendroglioma. 2002
2002 DNA topoisomerase IIα expression in optic pathway gliomas of childhood.  European journal of cancer.  38:393-400. 2002
2001 Anticancer drug resistance in primary human brain tumors.  Brain Research Reviews.  35:161-204. 2001
1999 Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood.  Clinical Cancer Research.  5:1786-1792. 1999
1999 The p21-Ras signal transduction pathway and growth regulation in human high-grade gliomas.  Brain Research Reviews.  29:232-249. 1999
1997 Basic fibroblast growth factor expression as a predictor of prognosis in pediatric high-grade gliomas.  Clinical Cancer Research.  3:2157-2164. 1997
1997 The role of protein kinase C (PKC) in the evolution and proliferation of malignant gliomas, and the application of PKC inhibition as a novel approach to anti-glioma therapy 1997

Chapter

Year Title Altmetric
2014 Primary Tumors of the Nervous System 2014
2013 Primary Tumors of the Nervous System.  1-22. 2013

Principal Investigator On

Investigator On

  • Private Grant  awarded by BLUE EARTH DIAGNONSTICS LTD ^ 2021 - 2025
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2019 - 2024
  • NRG Oncology Member Institution Clinical Trial Fixed Price Subaward Agreement  awarded by NRG ONCOLOGY FOUNDATION 2019 - 2024
  • XUAB 17109-TBCRC 038: Diversity in the Tumor Genome and Microenvironment as Drivers of DCIS Progression  awarded by Johns Hopkins University 2018 - 2023
  • Private Grant  awarded by VARIAN MEDICAL SYSTEMS, INC. 2019 - 2022
  • Private Grant  awarded by NOVOCURE, INC. 2019 - 2022
  • The Role of CK2 in Glioblastoma Development  awarded by National Cancer Institute/NIH/DHHS 2015 - 2021
  • Pragmatic Phase III Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial  awarded by University of Pennsylvania 2019 - 2021
  • TBCRC 038: Diversity in the Tumor Genome and Microenvironment as Drivers of DCIS Progession  awarded by Duke University 2018 - 2020
  • UAB NRG Oncology Master Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2019
  • Private Grant  awarded by NOVOCURE, INC. 2017 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2015 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2014 - 2019
  • Targeting the JAK/STAT-3 Pathway Signaling Axis in Glioma  awarded by National Cancer Institute/NIH/DHHS 2012 - 2018
  • Contemporary Therapeutics for Anaplastic Gliomas  awarded by National Cancer Institute/NIH/DHHS 2011 - 2017
  • Contemporary Therapeutics for Anaplastic Gliomas - Brain Tumor Tissue Core  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016

    • Education And Training

  • Doctor of Medicine, University of Vienna 2001
  • Doctor of Philosophy in Medical Neurobiology, Free University of Berlin 2001
  • UAB Hospital, Residency 2014
  • Stanford University School of Medicine, Postdoctoral Fellowship 2005

    • Full Name

  • Markus Bredel